Bayer’s Gadavist (gadobutrol) Injection Receives the US FDA’s Approval for use in CMRI in Patients with Coronary Artery Disease

Bayer's Gadavist (gadobutrol) Injection Receives the US FDA’s Approval for use in CMRI in Patients with Coronary Artery Disease

Shots:

  • The approval is based on two P-III studies evaluating the diagnostic results of Gadavist enhanced cardiac MRI to assess myocardial perfusion and late gadolinium enhancement in adult patients with CAD
  • Gadobutrol-enhanced cardiac MRI demonstrated efficacy in global clinical studies and provide details about the functions of the heart muscles to support the management of patients with CAD
  • Gadavist is an approved contrast agent in >100 countries including the US, EU, Japan for multiple indications i.e, CE-MRA, CE-MRI of the liver and kidneys, CNS and all body regions

Click here to read full press release/ article | Ref: Bayer | Image: Office Snapshots